BioCell Innovations, a Singapore-based biotechnology startup pioneering next-generation CAR-T therapies, has been awarded a G-Rex Grant ($125,000) from ScaleReady to integrate its proprietary CAR manufacturing process with the highly efficient G-Rex platform.
BioCell Innovations has introduced a proprietary CAR-T manufacturing process that dramatically reduces cytokine-associated toxicities, particularly cytokine release syndrome (CRS), without compromising therapeutic potency. This next-generation platform delivers a cost-effective, scalable, and clinically adaptable solution, prioritising both patient safety and treatment efficacy.
“With the support of this grant, we aim to seamlessly integrate our manufacturing process into the G-Rex system, accelerating the clinical deployment of a safer and more effective CAR-T product,” said Dr Paula Lam, Chief Scientific Officer at BioCell Innovations.
“Optimising CAR-T manufacturing is more than scientific innovation; it's a commitment to accessibility. The G-Rex Grant empowers us to refine and scale BC-003 production, enhancing efficiency expanding access to innovative immunotherapies to more patients in need” added Dr Fazil Turabe, Head of Research & Development.
BC-003 is a dual targeting CD19-CD20 CAR-T product designed to target B-cell malignancies, including relapsed and refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. By simultaneously engaging CD19 and CD20, BC-003 aims to overcome antigen escape mechanisms and improve therapeutic efficacy.
The G-Rex Grant Programme is a $20 million initiative launched by ScaleReady in collaboration with Wilson Wolf Manufacturing. It aims to accelerate innovation in cell and gene therapy (CGT) development, and thus supporting companies like BioCell to deliver real-world solutions through precise CAR-T manufacturing.
